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An unexpected role for a Mediator subunit, MED12, in resistance to multiple anticancer agents is
revealed by Huang et al. Loss of MED12 confers drug resistance by activating transforming growth
factor b (TGF-b) signaling. Inhibition of the TGF-b pathway resensitizes cells to therapeutic drugs,
suggesting a new combinatorial cancer treatment.Carcinogenesis is frequently associated
with aberrant kinase activities in trans-
formed cells. Potent and specific kinase
inhibitors represent an important compo-
nent of targeted cancer therapy, which
has become part of many cancer treat-
ment regimens because of its precision
in killing cancer cells with relatively few
side effects as compared to traditional
chemotherapies. In the anticancer war,
however, precision may also mean nar-
rowness, which is an intrinsic drawback
of targeted cancer therapy because it
often allows cancer cells to regroup, that
is, develop drug resistance, one of the
primary reasons for treatment failure. In
this issue, Bernards and colleagues report
the results of a screen with short hairpin
RNA (shRNA)-mediated knockdown that
identifies a common determinant of drug
resistance in several cancer cell lines
(Huang et al., 2012) (Figure 1).
Our knowledge on cancer drug resis-
tance is far from complete due to the
complexity of the disease and variation
among patients. In some cases, drug re-
sistance is inherent to cancer cells but
can also be acquired under selective
pressure via a number of distinct mecha-
nisms (Gottesman, 2002). Understanding
these mechanisms can yield great clinical
benefits for predicting patient responses
and devising alternative treatment strate-
gies (Bock and Lengauer, 2012).
Large-scale screens in cancer cell lines
with expression clones, shRNAs, or small
compounds are widely used to identify
factors that confer or prevent resistance
to a particular anticancer treatment. In
the current work, Huang et al. started
with a lung cancer line harboring a translo-
cation between EML4 and the kinase
ALK, which are sensitive to ALK inhibitors.They screened 24,000 shRNAs targeting
8,000 human genes in the hope of discov-
ering gene products that would enable
cancer cell growth in the presence of the
drugs. One particular hit met their strin-
gent criteria, and strikingly, knockdown
of the gene in different types of cancer
cells leads to broad drug resistance.
These cells continue to grow in the pres-
ence of inhibitors against receptor tyro-
sine kinases (RTKs), BRAF, and MEK
and are still capable of maintaining rela-
tively high activity of ERK.
The gene target identified is an unex-
pected one, MED12, which encodes a
subunit of the Mediator complex that is
essential for gene transcription in all
eukaryotic cells. Consisting of at least
26 subunits, the Mediator complex is a
dynamic and sophisticated regulatory
unit that has been extensively studied
for its role in chromatin remodeling,
transcription factor recognition, RNA
polymerase II (Pol II) recruitment and
stabilization, and transcription initiation/
elongation (Taatjes, 2010). Several Medi-
ator subunits, including cyclin-dependent
kinase 8 (CDK8), CYCLIN C, MED12, and
MED13, form the so-called CDK8 sub-
module that reversibly interacts with
Mediator. The CDK8 complex can both
positively and negatively regulate gene
transcription and has been implicated in
carcinogenesis (Taatjes, 2010).
How does MED12, a subunit of the
nuclear CDK8-Mediator complex, re-
gulate cytoplasmic signal transduction
from RTKs to ERK and control responses
to anticancer drugs? To answer this ques-
tion, Huang et al. performed a second
round of shRNA screen specifically look-
ing for kinases that are necessary for
the acquired drug resistance in MED12Cell 151, Nknockdown cells. Again, they identify
one target that fulfills all the criteria of
the screen, and that gene encodes the
type II receptor of transforming growth
factor b (TGF-bR2). Depletion of TGF-
bR2 restores drug sensitivity of MED12-
deficient cancer cells.
In the canonical TGF-b pathway, TGF-
bR2 activates TGF-bR1, another receptor
serine/threonine kinase, which in turn
phosphorylates transcription factors
SMAD2 and SMAD3. The Smads then
translocate to the nucleus and regulate
the expression of TGF-b target genes. A
non-SMAD pathway also exists that
transduces signals from TGF-bRs to
MAPKs such as ERK (Massague´, 2012).
In fact, Huang et al. find that MED12
knockdown in the cancer cells causes
an upregulation of TGF-bR2 protein that
is sufficient to trigger downstream sig-
naling, both SMAD dependent and
independent. ERK is therefore activated
by this alternative mechanism, which
to a large extent explains the observed
drug resistance to RTK inhibitors.
Yet howdoesMED12 negatively control
TGF-bR2 protein levels? The authors
make another surprising discovery that
MED12 is also present and functions in
the cytoplasm where TGF-bR2 resides.
This property appears to be unique
to MED12 as other components of the
CDK8 submodule are not found outside
the nucleus, nor are they involved in regu-
lating drug resistance. Imaging and
biochemical data suggest that MED12
physically and preferentially binds the
immature form of TGF-bR2 during its
secretion and somehow prevents its
glycosylation (which is required for TGF-
bR2 function) and/or delivery to the cell
surface. More details of this regulationovember 21, 2012 ª2012 Elsevier Inc. 927
Figure 1. MED12 and Cancer Drug Resistance
Cancer cells harboring hyperactive RTKs are normally sensitive to RTK inhibitors. shRNA-mediated knockdown of the Mediator subunit MED12 causes drug
resistance by increasing the level of TGF-bR2 (the type II receptor of transforming growth factor b), which activates the ERK and SMAD pathways. This leads to
cell proliferation and features of EMT. Inhibition of TGF-bRs inactivates ERK and SMADs, resensitizing MED12-deficient cells to anticancer agents.remain to be delineated, especially where
the interaction occurs in the secretory
pathway and how TGF-bR2 maturation is
affected by MED12. Nevertheless, the
findings clearly represent an intriguing
mechanism for modulating TGF-b sig-
naling and make one wonder whether
MED12 is also capable of controlling other
receptor proteins in a similar manner.
Another significant observation from
this study is that drug-resistant MED12
knockdown cancer cells exhibit a unique
gene-expression signature that is both
prognostic and predictive. First, this
signature shows features of epithelial-to-
mesenchymal transition (EMT), a process
strongly induced by TGF-b and often
associated with poor prognosis. Indeed,
colorectal cancer patients bearing the
MED12 knockdown signature have worse
clinical outcomes than those with a wild-
type MED signature. Whether EMT has
a causal role in drug resistance is an
interesting question that remains to be
addressed. Second, therapeutic drugs
such as MEK inhibitors, EGFR inhibitor,
and 5-Fluorouracil are more likely to
fail if the cancer cells show a MED12
knockdown pattern of gene expression.928 Cell 151, November 21, 2012 ª2012 ElseGiven that double depletion/inhibition of
MED12 and TGF-bR2 causes synthetic
lethality of cancer cells in the screen, a
personalized combinatory therapy (Kum-
mar et al., 2010) with both TGF-bR in-
hibitors and RTK inhibitors is worth ex-
ploring for treating patients with markers
of MED12 knockdown.
InMED12-deficient cancer cells, neither
the TGF-bR2 inhibitor nor RTK inhibitors
alone block growth, but they do so syner-
gistically. In addition, the authors note that
TGF-b treatment alone impedes cancer
cell proliferation, whereas it provides
a selective advantage only when the cells
are challenged with anticancer drugs.
These observations reiterate two impor-
tant features of TGF-b signaling: (1) it
constantly cross-talks with other path-
ways (Guo and Wang, 2009), and (2) it
plays a dual role in cancer formation and
progression (Massague´, 2012). It will be
interesting to further dissect the indi-
vidual and combined contributions of the
SMAD and non-SMAD pathways to drug
resistance and EMT in a broader setting
and to identify the switch between the
anti- and protumorigenic functions of
TGF-b.vier Inc.There are several other important ques-
tions regarding this new drug-resistance
mechanism. First, MED12 is mostly
point-mutated rather than deleted in
human cancers (Ma¨kinen et al., 2011),
and mutant MED12 is also implicated in
noncancer genetic disorders. How is
MED12 function altered by those muta-
tions, and are thosemutants also involved
in cancer drug resistance? Second,
CDK8 phosphorylates the linker region
of SMAD2/3, which couples SMAD
activation and degradation (Alarco´n
et al., 2009). It is unclear whether loss of
MED12 would influence the nuclear func-
tion of SMAD proteins in a CDK8-depen-
dent manner, which would in turn regulate
cell proliferation, EMT, or responses to
drugs. Third, can TGF-bR inhibitors be
used to target cancer stem cells, which
are notorious for their resistance to anti-
cancer therapies (Dean et al., 2005)?
Lastly, one obvious caveat of studies
with cancer cell lines is that they cannot
reflect the importance of the stroma and
microenvironments within a tumor, which
are also critical determinants of drug
responses. Careful validation with in vivo
models will be needed to convert these
exciting findings into effective weapons in
the battle against cancer.REFERENCES
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In this issue and in a recent issue of Cell, Vahedi et al. and Samstein et al. provide new insights into
the strategies used to establish an enhancer landscape during development of cell lineages. They
report that enhancer landscapes characterizing T cell lineages are pre-established and strongly
influenced by environmental stimuli.Transcription in eukaryotes is regulated
by sequence-specific DNA-binding pro-
teins associated with a gene’s promoter,
which encompasses the transcription
start site, and also by one or more distant
control regions, including enhancers.
Enhancers typically bind several DNA-
binding proteins and coregulatory pro-
teins that modulate chromatin structure
and directly communicate with the tran-
scription machinery positioned at the
promoter. Until recently, our knowledge
was based on studies of only a small
number of model enhancers because
enhancers were difficult to identify at a
genome-wide scale. During the past few
years, postgenomic technologies have re-
vealed characteristic features of poised
and active enhancers that have facilitated
enhancer discovery. By taking advantage
of this newfound capability, Vahedi et al.
(2012) and Samstein et al. (2012) in this
issue and in a recent issue of Cell have
expanded our knowledge of the diverse
strategies used to activate enhancersduring the development of mammalian
cell lineages.
Vahedi et al. (2012) focused on
active enhancers in two subtypes of
mature helper T cells—Th1 and Th2
cells—which, in a simplistic view, pro-
mote immune responses to intracellular
and extracellular microbial pathogens, re-
spectively. These two cell types develop
from the same naive Th cell precursor
upon T cell receptor (TCR) engagement
in the presence of different cytokine
signals. Th1 development is catalyzed
by IL-12 and IFN-g, which activate the
STAT4 and STAT1 transcription factors,
respectively. Among themany genes acti-
vated by these STAT proteins in the naive
Th cell is Tbx21, which encodes the T-bet
transcription factor that is considered to
be a master regulator of Th1 develop-
ment. In contrast, Th2 development is
catalyzed by IL-4, which activates the
STAT6 transcription factor that cooper-
ates with the Th2-specifying factor,
GATA3.To identify enhancers that are active in
mature Th1 and Th2 cells, Vahedi et al.
(2012) performed chromatin immunopre-
cipitation sequencing (ChIP-seq) analysis
for the transcriptional coactivator and
histone acetyltransferase, p300. The sig-
nificance of p300 association is thought
to be distinct from that of another promi-
nent enhancer mark, monomethylation
of histone H3 at lysine 4 (H3K4me1).
H3K4me1 is thought to mark both active
enhancers and inactive enhancers that
are poised for activation, whereas p300
is more closely associated with active
enhancers (Heintzman et al., 2007; Visel
et al., 2009; Ghisletti et al., 2010).
The first surprise to emerge from this
analysis was that a high percentage of
p300-marked regions (excluding pro-
moter regions) differed between the
closely related Th1 and Th2 populations;
45% and 35% of p300 peaks were
unique to Th1 or Th2 cells, respectively.
Remarkably, extending the analysis to
macrophages and embryonic stem cellsovember 21, 2012 ª2012 Elsevier Inc. 929
